Get the Stockscreener App
1.82
12.50%
0.22
Fibrobiologics Inc stock is traded at $1.82, with a volume of 1.94M.
It is up +12.50% in the last 24 hours and down -20.35% over the past month.
FibroBiologics Inc is a clinical-stage cell therapy company focused on developing and commercializing fibroblast-based therapies for patients suffering from chronic diseases with significant unmet medical needs, including degenerative disc disease, multiple sclerosis, wound healing, and certain cancers, and potential extension of life applications including thymic and splenic involution reversal.
See More
Previous Close:
$1.60
Open:
$1.77
24h Volume:
1.94M
Relative Volume:
9.56
Market Cap:
$58.25M
Revenue:
-
Net Income/Loss:
$-17.78M
P/E Ratio:
-3.3139
EPS:
-0.5492
Net Cash Flow:
$-10.52M
1W Performance:
+11.80%
1M Performance:
-20.35%
6M Performance:
-51.74%
1Y Performance:
-79.26%
1-Day Range:
$1.75
$2.00
1-Week Range:
$1.54
$2.00
52-Week Range:
$1.0779
$17.75
Fibrobiologics Inc Stock (FBLG) Company Profile
Name
Fibrobiologics Inc
Sector
Industry
Phone
281-671-5150
Address
455 E. MEDICAL CENTER BLVD, HOUSTON
Compare FBLG with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
FBLG
Fibrobiologics Inc
|
1.82 | 58.25M | 0 | -17.78M | -10.52M | -0.5492 |
|
VRTX
Vertex Pharmaceuticals Inc
|
473.24 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
715.00 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
653.00 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
274.48 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
118.55 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Fibrobiologics Inc Stock (FBLG) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-12-24 | Initiated | Rodman & Renshaw | Buy |
| Oct-30-24 | Initiated | H.C. Wainwright | Buy |
| Sep-24-24 | Initiated | Maxim Group | Buy |
Fibrobiologics Inc Stock (FBLG) Latest News
FibroBiologics Inc (NASDAQ: FBLG) Has Decreased By -81.41 Percent This Year. Is It A Better Buy Than Others? - Marketing Sentinel
Should You Invest in FibroBiologics Inc (FBLG) Now? - The News Heater
FibroBiologics to Host In-Person Analyst Day to Provide Research & Development Updates - GlobeNewswire
Exclusive Analyst Day: FibroBiologics to Unveil Future of Fibroblast Therapeutics - StockTitan
FibroBiologics And 2 Other US Penny Stocks To Watch - Simply Wall St
BlackRock, Inc. Increases Stake in FibroBiologics Inc - GuruFocus.com
FibroBiologics approves executive bonuses for fiscal 2024 - MSN
FibroBiologics approves executive bonuses for fiscal 2024 By Investing.com - Investing.com Canada
FibroBiologics, Inc. (NASDAQ:FBLG) Shares Bought by Barclays PLC - Defense World
Jane Street Group LLC Acquires Shares of 11,852 FibroBiologics, Inc. (NASDAQ:FBLG) - Defense World
Geode Capital Management LLC Acquires 284,047 Shares of FibroBiologics, Inc. (NASDAQ:FBLG) - Defense World
Barclays PLC Buys 31,331 Shares of FibroBiologics, Inc. (NASDAQ:FBLG) - Defense World
FibroBiologics, Inc. (NASDAQ:FBLG) Shares Bought by State Street Corp - Defense World
FibroBiologics Secures Second Tranche of $5 Million Financing - Defense World
FibroBiologics Announces $25 Million Financing - citybiz
FibroBiologics Closes Second $5 Million Tranche of $25 Million Financing - GlobeNewswire
FibroBiologics Secures Second $5M Tranche of $25M Equity Purchase Agreement with Yorkville Advisors - StockTitan
D. Boral Capital Served as Exclusive Placement Agent to FibroBiologics, Inc. (Nasdaq: FBLG) in connection with its $25.0 Million Financing - The Manila Times
D. Boral Capital Served as Exclusive Placement Agent to FibroBiologics, Inc. (Nasdaq: FBLG) in connection with its $25.0 Million Financing - GlobeNewswire Inc.
FibroBiologics (NASDAQ:FBLG) Receives Buy Rating from D. Boral Capital - Defense World
D. Boral Capital Reiterates Buy Rating for FibroBiologics (NASDAQ:FBLG) - MarketBeat
**FibroBiologics Enters Standby Equity Purchase Agreement for $25 Million Financing** ** - Defense World
FibroBiologics announces $25 million financing - MSN
FibroBiologics, Inc. announced that it expects to receive $15 million in funding from Yorkville Advisors Global LP - Marketscreener.com
FibroBiologics secures $25 million equity deal with Yorkville - Investing.com
FibroBiologics Secures $25M Equity Agreement for Trials - TipRanks
FibroBiologics Secures $25M Financing Deal to Advance Clinical Trials in Diabetic Foot Ulcers, Psoriasis - StockTitan
FibroBiologics finalizes agreement and terminates warrant By Investing.com - Investing.com Canada
FibroBiologics finalizes agreement and terminates warrant - Investing.com
Ionq Inc (IONQ-N) QuotePress Release - The Globe and Mail
FibroBiologics, Inc. (NASDAQ:FBLG) Short Interest Update - MarketBeat
Rodman & Renshaw Initiates Coverage of FibroBiologics (FBLG) with Buy Recommendation - MSN
FibroBiologics (NASDAQ:FBLG) Coverage Initiated at Rodman & Renshaw - MarketBeat
FibroBiologics, Inc. (NASDAQ:FBLG) Short Interest Up 7.2% in November - MarketBeat
FBLG: On Target to Initiate Phase 1/2 Trial in 2025… - MSN
FibroBiologics Files Patent Application for a Cell-based Therapeutic for the Treatment Of Splenomegaly - GlobeNewswire
FibroBiologics seeks patent for spleen disorder treatment By Investing.com - Investing.com Australia
FibroBiologics seeks patent for spleen disorder treatment - Investing.com India
FibroBiologics Files Patent for Breakthrough Splenomegaly Cell Therapy Treatment | FBLG Stock News - StockTitan
HC Wainwright Expects Stronger Earnings for FibroBiologics - MarketBeat
HC Wainwright Reaffirms Buy Rating for FibroBiologics (NASDAQ:FBLG) - Defense World
Fibrobiologics Files Patent Application Covering Reduction of Blood Clots Associated with Instant Blood-Mediated Inflammatory Reaction in Cell-Based Therapeutics - Marketscreener.com
FibroBiologics files patent for reducing cell therapy risks - Investing.com
FibroBiologics seeks patent for clot-prevention method - Investing.com
FibroBiologics Files Patent Application Covering Reduction of Blood Clots Associated with Instant Blood-Mediated Inflammatory Reaction (IBMIR) in Cell-Based Therapeutics - GlobeNewswire
FibroBiologics Files Patent Application Covering Reduction of Blood Clots Associated with ... - The Bakersfield Californian
FibroBiologics Files Patent for Breakthrough Cell Therapy Blood Clotting Prevention | FBLG Stock News - StockTitan
Is FibroBiologics (NASDAQ:FBLG) In A Good Position To Deliver On Growth Plans? - Yahoo Finance
FibroBiologics' (FBLG) Buy Rating Reaffirmed at HC Wainwright - MarketBeat
FibroBiologics Reports Third Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewswire
FibroBiologics Reports Wider Q3 Loss, Advances Clinical Pipeline Amid R&D Push | FBLG Stock News - StockTitan
Fibrobiologics Inc Stock (FBLG) Financials Data
Revenue
Net Income
Cash Flow
EPS
Fibrobiologics Inc Stock (FBLG) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Khoja Hamid | Chief Scientific Officer |
Aug 12 '24 |
Buy |
1.90 |
10,000 |
19,000 |
11,250 |
0.61%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):